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Abstract
Background: IgA nephropathy (IgAN) involves mesangial matrix expansion, but the proteomic composition of this
matrix is unknown. The present study aimed to characterize changes in extracellular matrix in IgAN.
Methods: In the present study we used mass spectrometry-based proteomics in order to quantitatively compare
protein abundance between glomeruli of patients with IgAN (n = 25) and controls with normal biopsy findings (n =
15).
Results: Using a previously published paper by Lennon et al. and cross-referencing with the Matrisome database
we identified 179 extracellular matrix proteins. In the comparison between IgAN and controls, IgAN glomeruli
showed significantly higher abundance of extracellular matrix structural proteins (e.g periostin, vitronectin, and
extracellular matrix protein 1) and extracellular matrix associated proteins (e.g. azurocidin, myeloperoxidase,
neutrophil elastase, matrix metalloproteinase-9 and matrix metalloproteinase 2). Periostin (fold change 3.3) and
azurocidin (3.0) had the strongest fold change between IgAN and controls; periostin was also higher in IgAN
patients who progressed to ESRD as compared to patients who did not.
Conclusion: IgAN is associated with widespread changes of the glomerular extracellular matrix proteome. Proteins
important in glomerular sclerosis or inflammation seem to be most strongly increased and periostin might be an
important marker of glomerular damage in IgAN.
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Background
IgA nephropathy (IgAN) is the most prevalent primary
chronic glomerular disease worldwide [1], and although
benign in many cases, it is reported that up to 30–50%
will slowly progress to end stage renal failure [2, 3]. The
pathogenesis of IgAN involves mesangial deposition of
immune-complexes containing galactose deficient IgA1
that leads to mesangial cell activation and initiation of
glomerular injury [4]. Mesangial proliferation is scored
in the Oxford classification of IgAN and has been shown
to predict progressive disease [5]. Activated mesangial
cells secrete inflammatory mediators and components of
the extracellular matrix, and mesangial hypercellularity
is thus morphologically often associated with increase of
extracellular matrix (ECM).
The glomerular extracellular matrix is a dynamic
structure which acts both as structural support for the
cells and as an active component in cell signaling [6].
Lennon et al. previously described the protein compos-
ition of the glomerular ECM, identifying 144 structural
and regulatory ECM proteins [7]. Recently, Hobeika
et al. [8] expanded the list by including their identified
proteins from microdissected glomerular tissue and
comparing with proteins described in the Matrisome
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project database - a curated database of ECM structural
and associated proteins [9], http://matrisomeproject.mit.
edu/. IgAN is a disease characterized by glomerular
ECM expansion, but the glomerular proteomic changes
have not been investigated in detail.
In the present study we microdissected glomerular tis-
sue from 25 patients with IgAN and 15 patients with
normal findings on kidney biopsy (controls) in order to
investigate glomerular ECM proteins which either had
been defined by Lennon et al. [7] or by the Matrisome
project database. Our hypothesis was that composition
of glomerular ECM would be changed in IgAN as com-
pared to controls and that some ECM proteins would
also be associated with progressive clinical course in
IgAN. An improved understanding of these changes may
be important for a better understanding of the glomeru-
lar damage in IgAN.
Methods
Registries used in the study
The patients were selected from Norwegian Kidney Bi-
opsy Registry. Data on end stage renal disease (ESRD)
were retrieved by linking data with data from the Nor-
wegian Renal Registry. We calculated GFR based on The
chronic kidney disease - Epidemiology Collaboration
(CKD-EPI) equation [10]. Urinary protein was quantified
as grams/24 h, as previously described [11], either from
directly measured values, by calculation from reported
urinary protein to creatinine ratio or if only reported by
urinary dipstick a negative dipstick was set to 0 g/24 h,
1+ was set to 0.5 g/24 h, 2+ was set to 1.0 g/24 h and 3+
was set to 3.0 g/24 h.
Study population
IgAN patients with an estimated glomerular filtration
rate (GFR) of > 45ml/min/1.73m2 were selected for the
study. In total 25 IgAN patients were included in the
study, these were divided based on whether or not they
progressed to ESRD (defined as time to dialysis or trans-
plantation) during the first 10 years after being diag-
nosed: 16 patients with non-progressive IgAN and 9
patients with progressive IgAN. In addition, 15 patients
with normal findings on kidney biopsy (most common
biopsy indication hematuria and/or microalbuminuria)
and with estimated glomerular filtration rate of > 60ml/
min/1.73m2, proteinuria < 0.5 g/24 h and available kidney
tissue were included as controls (only one control pa-
tient had GFR < 90 ml/min/1.73m2). The study was ap-
proved by the Regional Committee for Medical and
Health Research Ethics (approval number 2013/553).
Laser capture microdissection
As previously described [11], formalin-fixed paraffin-
embedded tissue (FFPE) from the remaining part of
the kidney biopsy core that was not used for diagnos-
tics was cut into five micrometer thick sections,
mounted on pre-irradiated polyethylene naphthalate
slides, deparaffinized and stained with hematoxylin
eosin. Approximately 100 glomerular cross sections
were laser microdissected by the first author and col-
lected into specialized tubes for each sample. We ex-
cluded glomeruli with global sclerosis, more than
minimal segmental sclerosis, crescents or fibrinoid ne-
crosis. Protein extraction was performed as described
in a previous article [12].
Liquid chromatography and tandem mass spectrometry
We used a Q-Exactive HF (Thermo Scientific) connected
to a Dionex Ultimate NCR-3500RS liquid chromatog-
raphy (LC) system to analyze the samples, as previously
described (Additional files) [11].
Data analysis
The data were analyzed in the same manner as our pre-
vious article [11]. In short, we used Progenesis with de-
fault settings for raw data analysis, Proteome Discoverer
for protein identification (using the SwissProt human
database) and Perseus software (v1.5.0.0) [http://perseus-
framework.org/] for the analyses.
Histology and immunohistochemistry
An experienced nephropathologist (SL) scored the biop-
sies in a blinded manner using the Oxford classification
scoring system [13]. Immunohistochemistry for periostin
(Sigma HPA012306, 1:50) was performed after heat-
induced antigen retrieval. The tissue glass slides were
scanned with ScanScope® XT (Aperio) at × 40. The slides
were viewed in ImageScope 12. Periostin expression in
glomeruli was quantified by image analysis with the al-
gorithm Positive Pixel Count V9 (Aperio/Leica). Each
glomerulus was manually selected and analyzed for pixel
intensity; pixels with intensity between 0 and 150 were
defined as positive. Number of positive pixels was di-
vided by total number of pixels per glomerulus, thus
yielding a proportion of positive pixels per glomeruli.
For each patient sample, mean proportion of positive
pixels was calculated and these were compared between
groups.
Statistics
The relative differences in protein abundance are given
as fold change. Statistical analysis of proteins abundance
between groups was performed with Student’s t-test on
log transformed intensity data. For other analyses,
mean ± standard deviation (SD) is given. Standard two-
sided t-tests were used, and p-values of < 0.05 were con-
sidered statistically significant.
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Results
Patient characteristics
The clinical characteristics of patients with IgAN (n =
25) and of controls (n = 15) are shown in Table 1. As
compared to controls, IgAN patients were more often
male, had more proteinuria and tended to have higher
systolic blood pressure. IgAN patients with progressive
and non-progressive disease course did not differ in
these clinical characteristics. Three of the patients with
IgAN had received steroid treatment after diagnosis with
at least 20 mg prednisolone daily for at least 1 month
(one non-progressor and 2 progressors). Use of angio-
tensin inhibition treatment has not been reliably regis-
tered in the registry.
Overall proteome analysis
In total, 3274 different proteins were identified in the
analyses, of which 2018 were identified with two or more
unique peptides and were included in the quantitative
analyses. To detect potential outlier samples, we per-
formed a multi-correlation analysis (Pearson correlation)
where each sample-sample correlation was visualized by
hierarchical clustering (Additional file 1: Figure S1). The
correlation analysis showed high correlation between
samples (0.77–0.97) indicating reliable sample process-
ing, microdissection and proteomics and that samples
were comparable.
Extracellular matrix proteome
Proteins were defined as related to the extracellular
matrix if the protein were 1) found in the Matrisome
project database (10, 1027 proteins, extracted 15.05.17),
or 2) identified in the glomerular ECM enrichment study
by Lennon et al. (144 proteins) [7]. This yielded a list of
179 ECM proteins (Fig. 1a, Additional file 2: Table S1).
Proteins were grouped using the same approach as
Lennon et al. [7].
Of the 179 proteins, 108 had been grouped by Lennon
et al. (20 as glomerular basement membrane (GBM)
proteins; 14 as other structural ECM proteins and 74 as
ECM associated proteins) [7]. The remaining 71 proteins
were classified in the Matrisome dataset, either as core
proteins (22 proteins) or as Matrisome - associated (49
proteins) and we further classified this proteins using
gene ontology annotations into GBM proteins (n = 5),
structural ECM (n = 17) and ECM associated proteins
(n = 49). Of the 179 proteins, 123 proteins overlapped
with the proteins identified by Hobeika et al. who in-
cluded proteins described by Lennon as well as proteins
from their study of microdissected glomeruli that had
been described in the Matrisome database (Fig. 1b).
Basement membrane proteins
We were able to quantify 25 basement membrane pro-
teins (Additional file 3: Table S2). In addition to 20
Table 1 Patient’s characteristics
Controls IgAN total IgAN without progression IgAN with progression
N 15 25 16 9
Year of diagnosis 2000 ± 7.7 1997 ± 4.4 1996 ± 3.4 1998 ± 5.7
Proportion female 53.3% 20% 12.5% 33.3%
Age (years) 32.0 ± 11.9 31.3 ± 14 31.4 ± 13.4 31.2 ± 15.8
Serum creatinine (mmol/l) 79.3 ± 20.9 96.6 ± 23.6 * 91.5 ± 21.5 105.8 ± 25.6*
Estimated glomerular filtration rate ª (ml/min/1.73m2) 113.13 ± 18.5 106.16 ± 27.43 114.19 ± 25.3 91.89 ± 26.3*
Systolic blood pressure (mmHg) 118.6 ± 14.6 130.2 ± 19.2 127.2 ± 14.3 135.4 ± 25.8
Diastolic blood pressure (mmHg) 77.6 ± 8.4 78.8 ± 11.9 78.9 ± 11.6 78.8 ± 13.1
Urinary protein (grams/24 h) 0.16 ± 0.17 1.7 ± 1.03 * 1.76 ± 1 * 2.0 ± 2.0 *
Body weight (kg) 74.7 ± 11.9 75.8 ± 9.9 76.1 ± 8.0 75.4 ± 12.5
No of years of follow-up 12.3 ± 7.7 16.3 ± 3.4
No of years from biopsy to ESRD 5.8 ± 2.5
Percentage with M-score of 1b Not applicable 36% 31.3% 44.4%
Percentage with E-score of 1b Not applicable 32% 31.3% 33.3%
Percentage with S-score of 1b Not applicable 60% 50% 77.8%
Percentage with T-score of 1 or 2b Not applicable 16% 0% 44.4% **
Percentage with C-score of 1b Not applicable 4% 0% 11.1%
*p < 0.05 as compared to control
**p < 0.05 IgAN with progression as compared to IgAN without progression
ª Estimated by CKD-EPI equation
b According to Oxford Classification
Paunas et al. BMC Nephrology          (2019) 20:410 Page 3 of 12
proteins previously identified by Lennon et al. and
Hobeika et al. [7, 8], our dataset contained 5 additional
proteins (laminin subunit alpha-1, netrin-4, multimerin-
2, papilin and tenascin). Of the basement membrane
proteins, 10 were significantly more abundant in IgAN
as compared to controls and four of these had a fold
change of at least 1.5 (collagen alpha-1 (XV) chain,
tenascin, collagen alpha-1 (IV) chain and fibronectin)
(Table 2). In the comparison between progressive IgAN
as compared to non-progressive IgAN, there were 3 sig-
nificantly different proteins, 1 was more abundant (von
willebrand factor A domain-containing protein 1), and 2
Fig. 1 a We combined our protein list of quantified proteins with the protein list from the Matrisome project database (n = 1027) and the list
from Lennon et al. (n = 144 proteins). b. Comparison of our list of ECM proteins with the protein list from Lennon et al. [7] and Hobeika et al. [8]
Table 2 Basement membrane proteins identified in our study sorted by fold change between IgAN and control patients. The linear
and mesangial matrix staining patterns were assessed by visual inspection of staining in humanproteinatlas.org
Protein Name Gene
Name






Fold change P-value Fold change P-value
Collagen alpha-1(XV) chain COL15A1 P39059 2.39 0.03 2.30 0.10 Yes Yes
Tenascin TNC P24821 1.85 0.0001 1.16 0.51 Yes Yes
Collagen alpha-1(IV) chain COL4A1 P02462 1.54 0.000003 1.10 0.88 Yes Yes
Fibronectin FN1 P02751 1.50 0.00004 1.17 0.12 Yes Yes
Collagen alpha-2(IV) chain COL5A2 P08572 1.38 0.0003 0.99 0.76 Not detected Not detected
von Willebrand factor A domain-containing
protein 1
VWA1 Q6PCB0 1.36 0.01 1.41 0.01 Pending tissue analysis
Nidogen-2 NID2 Q14112 1.33 0.0004 1.13 0.62 Yes Yes
Laminin subunit beta-1 LAMB1 P07942 1.33 0.003 1.05 0.52 Yes Yes
Basement membrane-specific heparan
sulfate proteoglycan core protein
HSPG2 P98160 1.33 0.002 1.08 0.97 Yes Yes
Fibulin-1 FBLN1 P23142 1.32 0.01 1.35 0.20 Yes Yes
Only proteins significantly changed between IgAN and controls are shown. Full protein list is shown in Additional file 3: Table S2
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less abundant (agrin and laminin subunit beta-2). By
analyzing staining patterns in the human protein atlas
[https://www.proteinatlas.org] we found that most of the
proteins previously described as basement membrane
proteins also showed positive staining in the glomerular
mesangium (Table 2).
Structural ECM proteins
We were able to quantify 31 structural ECM proteins
(Additional file 4: Table S3). Of these, 14 were previous
identified by Lennon et al. and 13 by Hobeika et al. Seven-
teen proteins were unique to this study. Of the 31 proteins,
11 proteins were significantly different between IgAN and
control (Table 3), of which 10 proteins were more abun-
dant and 1 less abundant. Between progressive IgAN and
non-progressive IgAN there were 2 significantly more
abundant proteins: periostin and fibrinogen-like protein 1.
Periostin was the only protein that was significantly more
abundant both in IgAN as compared to control as well as
in progressive IgAN as compared to non-progressive IgAN,
periostin abundance for each patient is shown in Fig. 2.
ECM associated proteins
We quantified totally 123 ECM associated proteins, 74 had
been also found in the Lennon et al. study and 80 in the
Hobeika et al. study. Thirty-four proteins had not been previ-
ously described by Lennon et al. or Hobeika et al. Of these
123 ECM associated proteins, 11 were complement associ-
ated proteins and were not investigated further in the present
study as they have been discussed separately in a previous
paper of the same patients [11]. Of the remaining 112 ECM
associated proteins, 32 proteins were significantly different
between IgAN and control, 21 were more abundant and 11
less abundant (Table 4). By performing a literature search on
these proteins we found that most of them were related to
inflammation and immune response (eg azurocidin,
myeloperoxidase, neutrophil elastase, cathepsin G, annexin
A1, Protein S100-A9 etc), epithelial - mesenchymal trans-
formation (Protein-glutamine gamma-glutamyltransferase 2,
Protein S100-A4) and collagen synthesis (serpin H1, MMP2
and MMP9). Between progressive IgAN and non-
progressive IgAN there were four significantly different pro-
teins, three were more abundant (clusterin, apolipoprotein E,
apolipoprotein A IV,) and one less abundant (carbonic anhy-
drase 2).
Glomerular morphology and periostin staining
According to the Oxford classification, 36% of IgAN pa-
tients were classified as M1, 32% as E1, 60% as S1, 16%
as T1 or T2 and 4% as C1. No patient was classified as
C2. As expected, glomeruli from IgAN patients showed
more mesangial cell proliferation and matrix expansion
as compared to controls. Importantly, Oxford classifica-
tion of glomerular findings did not differ between non-
progressive and progressive IgAN patients, but progres-
sive IgAN patients had more often T1/T2 as compared
to non-progressive IgAN patients (0% Vs 44.4%). Immu-
nohistochemistry (IHC) for periostin was performed for
24 samples and examples of staining in the three groups
are shown in Figs. 3 a-c, Fig. 3d illustrates pixel analysis.
By image analysis, a higher proportion of pixels were
positive for periostin in the glomeruli of IgAN as com-
pared with controls (p-value = 0.003). There was no sig-
nificant difference in positivity between progressive and
non-progressive IgAN. Interestingly, there was signifi-
cant periglomerular positivity.
Could ECM protein abundance separate IgAN patients
from control patients?
As shown in Fig. 4a, principal component plot of the de-
scribed glomerular ECM proteins showed some separ-
ation of control and IgAN patients, but there was
Table 3 Structural ECM proteins identified in our study sorted by fold change between IgAN and control patients
Protein name Gene Name Uniprot ID IgAN total vs control IgA progr vs IgA non-progr
Fold change P-value Fold change P-value
Periostin POSTN Q15063 3.28 0.000001 1.79 0.04
EGF-containing fibulin-like extracellular matrix protein 1 EFEMP1 Q12805 1.89 0.002 1.08 0.98
Fibrinogen beta chain FGB P02675 1.87 0.001 1.10 0.71
Vitronectin VTN P04004 1.87 0.00001 1.16 0.18
Transforming growth factor-beta-induced protein ig-h3 TGFBI Q15582 1.80 0.001 1.13 0.65
Extracellular matrix protein 1 ECM1 Q16610 1.78 0.0003 1.30 0.70
Fibulin-5 FBLN5 Q9UBX5 1.76 0.002 0.70 0.85
Netrin-G1 NTNG1 Q9Y2I2 −1.17 0.03 1.19 0.80
Fibrinogen-like protein 1 FGL1 Q08830 1.60 0.04 1.69 0.045
Fibrinogen gamma chain FGG P02679 1.53 0.005 0.93 0.61
EMILIN-1 EMILIN1 Q9Y6C2 1.34 0.005 1.06 0.47
Only proteins significantly changed between IgAN and controls are shown. Full protein list is shown in Additional file 4: Table S3
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significant overlap. Principal component analysis of
the 20 most significantly changed proteins did how-
ever improve separation (data not shown), this would
also be expected but might argue for more direct im-
plications of specific ECM proteins in IgAN. This is
further shown in the unsupervised hierarchical clus-
tering map showing relative abundance of these pro-
teins in the individual patients and separation of
IgAN and control patients (Fig. 4b).
Glomerular ECM protein interaction network
All significantly changed ECM proteins identified in the
analysis between IgAN and control glomeruli were in-
cluded in a protein interaction network model using the
Search Tool for the Retrieval of Interacting Genes
(STRING v10) database with medium confidence score
0.4 (Fig. 5). It was clear that the three groups of proteins
that we have used for categorization in the present study
interacted strongly. Interestingly, several of the most sig-
nificantly changed proteins interacted with each other.
Periostin interacted for example with fibronectin,
MMP2, MMP9, annexin A2 and protein-glutamine
gamma-glutamyltransferase 2. Furthermore, collagen
alpha-1 (IV) interacted with other collagens, vitronectin
as well as TGF-beta induced protein and basement
membrane-specific heparan sulfate proteoglycan core
protein.
Discussion
In the present study we have investigated the glomerular
extracellular matrix (ECM) proteome in IgAN and quan-
titatively compared this to the proteome of glomeruli
from patients with normal findings on kidney biopsy.
We made several interesting findings. First, a high num-
ber of ECM associated proteins showed altered abun-
dance in IgAN as compared to controls, several of these
were related to inflammation, immune response and fi-
brosis development. Second, several structural ECM pro-
teins had increased abundance in IgAN compared with
controls and the protein with the strongest difference in
abundance was periostin. Periostin was also more abun-
dant in patients with progressive IgAN as compared to
patients with non-progressive IgAN. Third, basement
membrane proteins were increased in IgAN. Overall, our
study suggests that glomerular ECM changes in IgAN
have strong similarities to changes seen in fibrosis devel-
opment in general.
In IgAN mesangial IgA deposition and formation of
immune complexes leads to mesangial cell proliferation,
the release of proinflammatory mediators by mesangial
cells and matrix expansion [14]. In our study, most of
the ECM associated proteins which had higher
abundance in IgAN compared to controls were proteins
involved/associated with the immune response and in-
flammation (eg. azurocidin, myeloperoxidase, neutrophil
elastase, cathepsin G, annexin A1, protein S100-A9 etc).
Most of these proteins have been described as present in
polymorphonuclear leukocytes [15–17], and some may
also act as a chemoattractants and activators of mono-
cytes and macrophages [18]. To our knowledge the roles
of these proteins have not been described in IgAN, but
may mark underlying mechanisms of glomerular dam-
age. Inflammation is for example known to be a propa-
gator of fibrosis development in general [19].
Several structural ECM proteins, such as vitronectin,
extracellular matrix protein 1, fibulin-5 and fibrinogen
Fig. 2 Scatter plot illustrating label-free quantification intensities for Periostin between groups. Mean (standard deviation) and p-values are given
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were significantly more abundant in IgAN than in
controls. We had not microdissected glomeruli with
more than minimal sclerosis and our findings thus
most likely illustrate the proteomic changes in mesan-
gial expansion or early glomerular sclerosis. Several
proteins that have been shown to be involved in fi-
brosis development were shown to be more abundant
in IgAN compared with controls, such as periostin
[20], serpin H1 [21], MMP2 [22] and MMP9 [22, 23].
Periostin was also significantly more abundant in
IgAN patients who progressed to ESRD as compared
to IgAN patients who did not progress. In the kidney,
periostin has been implicated in progression of hyper-
tensive nephropathy [24] and it was increased in
glomeruli of patients with progressive proteinuric dis-
ease [25]. A recently published study showed that
periostin is induced by proinflammatory factors,
mainly NFκB in a model of chronic renal disease, and
that inhibition of periostin can be used as a thera-
peutic strategy to slow down renal disease progression
[26]. We are not sure why the findings of increased
abundance of periostin in progressive IgAN vs non-
progressive IgAN from the proteomic analysis were
not seen using immunohistochemistry analyses. We
Table 4 Significant ECM- associated proteins between IgAN vs Control proteins
Protein name Gene Name Uniprot ID IgAN total vs control IgAN progr vs IgAN non-progr
Fold change P-value Fold change P-value
Azurocidin AZU1 P20160 3.31 0.005 1.61 0.11
Secreted phosphoprotein 24 SPP2 Q13103 2.84 0.02 1.56 0.40
Myeloperoxidase MPO P05164 2.42 0.0003 1.22 0.08
Neutrophil elastase ELANE P08246 2.27 0.006 1.04 0.24
Matrix metalloproteinase-9 MMP9 P14780 2.05 0.0002 1.08 0.12
Neutrophil defensin 1 DEFA1 P59665 1.94 0.0003 1.24 0.27
Protein S100-A8 S100A8 P05109 1.93 0.04 0.94 0.44
Clusterin CLU P10909 1.92 0.0001 1.68 0.0004
Protein S100-A4 S100A4 P26447 1.87 0.04 1.67 0.07
Cathepsin G CTSG P26447 1.80 0.002 1.56 0.16
Annexin A3 ANXA3 P08311 1.77 0.047 0.97 0.65
Apolipoprotein E APOE P12429 1.73 0.00001 1.71 0.03
Protein-glutamine gamma-glutamyltransferase 2 TGM2 P02649 1.67 0.001 1.11 0.54
Protein S100-A9 S100A9 P21980 1.57 0.01 1.04 0.21
72 kDa type IV collagenase (Matrix metalloproteinase-2) MMP2 P06702 1.48 0.02 1.48 0.46
Annexin A1 ANXA1 P08253 1.45 0.01 1.12 0.82
Protein AMBP AMBP P04083 1.42 0.0002 1.32 0.48
CD59 glycoprotein CD59 P02760 1.39 0.01 1.26 0.14
Serpin H1 SERPINH1 P13987 1.33 0.01 1.16 0.52
Protein S100-A11 S100A11 P50454 1.31 0.01 1.13 0.06
Apolipoprotein A-IV APOA4 P31949 1.30 0.03 1.41 0.01
Alpha-1-antichymotrypsin SERPINA3 P06727 1.18 0.02 0.93 0.90
Beta-2-microglobulin B2M P01011 1.17 0.047 1.08 0.59
Peptidyl-prolyl cis-trans isomerase A PPIA P61769 −1.08 0.04 1.01 0.72
Annexin A2 ANXA2 P62937 −1.14 0.04 1.02 0.87
Phosphatidylethanolamine-binding protein 1 PEBP1 P07355 −1.30 0.003 0.87 0.88
Serpin B9 SERPINB9 P30086 −1.31 0.02 1.06 0.55
Carbonic anhydrase 2 CA2 P50453 −1.38 0.001 0.76 0.02
Galectin-3-binding protein LGALS3BP P00918 −1.46 0.01 0.85 0.59
Hornerin HRNR Q08380 −1.68 0.04 0.83 0.43
Syndecan-4 SDC4 Q86YZ3 −1.79 0.002 0.88 0.41
Inter-alpha-trypsin inhibitor heavy chain H5 ITIH5 P31431 −1.96 0.0002 1.21 1.00
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believe that the most likely explanation is that mass
spectrometry quantification is more precise than
quantification by immunohistochemistry.
Important proteins in matrix metabolism, MMP-9 and
MMP-2 were also significantly more abundant in IgAN
patients compared with controls. MMP-9 and MMP-2
are the most abundant intrarenal metalloproteinases [27]
and although it was initially thought that they were
mainly implicated in collagen degradation, MMP-2 has
been shown to have a pro-inflammatory effect by acting
on mesangial cells [28]. Both MMP-2 [29] and MMP-9
[30] are involved in the renal tubular cell epithelial–mes-
enchymal transition (EMT) and through that promoting
fibrosis. Future studies should investigate the roles of
these pathways in progressive glomerular sclerosis in
IgAN.
In a recent study by Liu et al., genes highly expressed
in mesangial cells discriminated better IgAN patients
from control patients than genes highly expressed in
podocytes and the study thus argued for a strong in-
volvement of mesangial cells in IgAN [31]. Few studies
have investigated the proteomic composition of mesan-
gial matrix in IgAN [32], and to our knowledge no previ-
ous studies have used modern proteomic approaches. As
discussed above, the proteomic changes of the glomeru-
lar ECM in our study have strong similarities with those
of fibrosis development in general. Mesangial matrix ex-
pansion has by many been regarded as a step towards
glomerular sclerosis, as was suggested in a review paper
by Fogo in 1999 [33], but there seem to be a paucity in
data on the underlying mechanisms of this process. Our
data and the Liu paper indicate important mechanisms
of this process that should be analyzed further.
Several proteins classically described as basement
membrane proteins were more abundant in IgAN com-
pared to controls, for example collagen alpha-1 (IV)
chain, fibronectin, laminin subunit beta-1, nidogen 1,
etc. We could not find studies of thickened GBM in
IgAN and previous studies reported rather thinning of
GMB in patients with IgAN [34, 35] Using immuno-
staining Masuda et al. [35] showed reduced α5 (IV) col-
lagen and increased α2 collagen as well as structural
changes of α5 (IV) collagen in patients with IgAN. They
reported thinning, irregular thickening, small gaps and
double contour of GBM examined by transmission elec-
tron microscopy [35]. By visually inspecting glomerular
staining for our proteins in the Human Protein Atlas we
did however observe that although these proteins
showed clear linear staining of the basement membrane,
they also showed positive mesangial staining. We
thereby believe that our findings represent changes in
the mesangial matrix rather than in the glomerular base-
ment membrane.
The most important strengths of the present study are
the large number of quantified proteins from microdis-
sected glomerular tissue. It is also a strength that we in-
cluded IgAN patients with moderate risk of progressive
disease (based on classical prognostic factors), a cohort
Fig. 3 a-d Periostin staining in the three patient groups a) Control patient with negative staining b) Non-progressive IgAN patient and c)
Progressive IgAN patient with more positive staining. There is week periostin staining for both IgAN without and with progression. d) Example of
Aperio pixel analysis of glomeruli in 3 c), orange and yellow indicate positive pixels and blue indicating negative pixels
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highly relevant for the clinical nephrologists and that we
could separate progressive from non-progressive pa-
tients. From a clinical perspective, the number of pa-
tients might seem low, but as compared to other
proteomic studies this is not the case and we would
argue that the similar clinical characteristics of the pa-
tients outweigh this limitation. As control group, we
used patients with normal kidney biopsy (indication of
biopsy was hematuria, proteinuria or reduced eGFR). An
extra control group of patients with similar eGFR and
another glomerulonephritis would have added more in-
formation regarding the particularly proteomic changes
that occur in IgAN versus chronic kidney disease in gen-
eral. It would however have been difficult to know which
particular disease to choose for such a comparison as
patients with hypertensive nephropathy, FSGS, or lupus
nephritis, will also differ from control in several aspects
and would have their own proteomic changes. In our
opinion, patients with normal kidney biopsy was a good
option as control group. As IgAN is an chronic kidney
disease we believe that there are many similarities with
CKD in general.
Although our control group was defined with GFR
over 60 ml/min/1.73m2, it is important to mention that
only one patient had GFR under 90ml/min/1.73m2 and
although the IgAN group was defined as GFR over 45
ml/min/1.73 m 2, only one patient had GFR under 60
ml/min/1.73 m 2.
The most common indication for biopsy was hematuria
(11 patients) or proteinuria (2 patients). This patients did
not have known hypertension, diabetes or malignancy and
the kidney biopsies were described as normal. It is import-
ant to keep in mind that although almost 200 extracellular
matrix proteins could be relatively quantified, the exact
Fig. 4 a Principal component analysis plot of extracellular matrix proteins. Green represents control patients; blue represents IgAN without progression
and red IgAN patients with progression. b Unsupervised hierarchical clustering map of the 20 most differently abundant glomerular proteins in patients
with IgAN as compared to controls. Each vertical bar represents a patient/control and each horizontal bar represents a protein. Red indicates more
abundant proteins while green less abundant proteins in IgAN vs controls. IgA + indicate progressive IgAN patients, IgA – indicate non progressors
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localization and role of these proteins could not be de-
scribed. It is for example possible that some of the pro-
teins are deposited intracellularly or have altered levels of
activity as compared to normal, we do however not believe
this to be the case for the majority of proteins.
Conclusion
In conclusion our study describes widespread proteome
changes of the extracellular matrix in IgAN and impli-
cates several proteins that may be important for devel-
opment of glomerular damage in IgAN. Most significant
Fig. 5 Glomerular ECM protein interaction network. Proteins significantly changed in IgAN glomeruli as compared to control glomeruli were
included in the analysis using the STRING database with medium confidence score (0.4). Lines of different color represent types of evidence used
in predicting associations. Red line: fusion evidence; green line: neighborhood evidence; blue line: co-occurrence evidence; purple line:
experimental evidence; yellow line: text mining evidence; light blue line: database evidence; black line: co-expression evidence. Figure is exported
from the string website
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proteins were related to inflammation and fibrosis in
general and periostin seem to be the most interesting
protein as abundance of this protein also could predict
progressive IgAN. More studies of the mechanisms link-
ing the described proteins with mesangial expansion and
glomerular damage are warranted.
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